| Literature DB >> 26811667 |
Keiichi Mitsuyama1, Mikio Niwa1, Hidetoshi Takedatsu1, Hiroshi Yamasaki1, Kotaro Kuwaki1, Shinichiro Yoshioka1, Ryosuke Yamauchi1, Shuhei Fukunaga1, Takuji Torimura1.
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic intestinal inflammation of unknown etiology. The diagnosis of IBD is based on endoscopic, radiologic and histopathologic criteria. Recently, the search for a noninvasive marker that could augment or replace part of this diagnostic process has become a focus of IBD research. In this review, antibody markers, including microbial antibodies, autoantibodies and peptide antibodies, will be described, focusing on their common features. At present, no single marker with qualities that are satisfactory for the diagnosis and treatment of IBD has been identified, although panels of some antibodies are being evaluated with keen interest. The discovery of novel IBD-specific and sensitive markers is anticipated. Such markers could minimize the use of endoscopic and radiologic examinations and could enable clinicians to implement individualized treatment plans designed to improve the long-term prognosis of patients with IBD.Entities:
Keywords: Biomarker; Crohn’s disease; Serological antibody; Ulcerative colitis
Mesh:
Substances:
Year: 2016 PMID: 26811667 PMCID: PMC4716040 DOI: 10.3748/wjg.v22.i3.1304
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742